The Efficacy and Safety of a Low-Dose Tranexamic Acid Bolus-Only Protocol Compared with the Moderate-Dose Protocol in Valvular Heart Surgery

Abstract

In 873 propensity score–matched pairs of patients undergoing valvular heart surgery, we compared a “moderate dose” of tranexamic acid (TXA) protocol (group 1; median TXA dose: 24 mg/kg body weight) with a 1.5-g “bolus-only” protocol (group 2; median TXA dose: 19 mg/kg body weight). The number of transfused patients was higher in group 2 than in group 1 (74.5 vs 66.0%, p < 0.001), as was the number of transfused red blood cell concentrates (p = 0.001). The risks of re-exploration and convulsive seizures were similar between groups (p > 0.50). Data indicate an impaired efficacy following the “bolus-only” protocol, without a significant safety improvement.

Keywords

cardiac - anesthesia - blood transfusion - heart valve surgery - neurology/neurologic

Publication History

Received: 13 October 2022

Accepted: 22 November 2022

Article published online:
19 January 2023

• References

• 1 Zufferey PJ, Lanoiselée J, Graouch B, Vieille B, Delavenne X, Ollier E. Exposure-response relationship of tranexamic acid in cardiac surgery. Anesthesiology 2021; 134 (02) 165-178
• 2 Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol 2016; 79 (01) 18-26
• 3 Hulde N, Zittermann A, Deutsch MA, von Dossow V, Gummert JE, Koster A. Moderate dose of tranexamic acid and complications after valvular heart surgery. Thorac Cardiovasc Surg 2023; 71 (03) 181-188
• 4 Jerath A, Yang QJ, Pang KS. et al. Tranexamic acid dosing for cardiac surgical patients with chronic renal dysfunction: a new dosing regimen. Anesth Analg 2018; 127 (06) 1323-1332
• 5 Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis 2019; 30 (01) 1-10
• 6 Grassin-Delyle S, Semeraro M, Lamy E. et al. Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth 2022; 128 (03) 465-472
• 7 Grassin-Delyle S, Theusinger OM, Albrecht R. et al. Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Anaesthesia 2018; 73 (06) 719-729
• 8 Abou-Diwan C, Sniecinski RM, Szlam F. et al. Plasma and cerebral spinal fluid tranexamic acid quantitation in cardiopulmonary bypass patients. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879 (7-8): 553-556
• 9 Hodgson S, Larvin JT, Dearman C. What dose of tranexamic acid is most effective and safe for adult patients undergoing cardiac surgery?. Interact Cardiovasc Thorac Surg 2015; 21 (03) 384-388
• 10 Shi J, Zhou C, Pan W. et al; OPTIMAL Study Group. Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: the OPTIMAL randomized clinical trial. JAMA 2022; 328 (04) 336-347